Shopping Cart
- Remove All
Your shopping cart is currently empty
Alacepril (DU-1219) is a relatively novel angiotensin-converting enzyme inhibitor, used as an antihypertensive

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | $50 | In Stock | |
| 25 mg | $81 | In Stock | |
| 50 mg | $122 | In Stock | |
| 100 mg | $182 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $55 | In Stock |
| Description | Alacepril (DU-1219) is a relatively novel angiotensin-converting enzyme inhibitor, used as an antihypertensive |
| In vivo | Treatment with alacepril improves functional status and exercise capacity in patients with mild-to-moderate CHF. Neurohormones were favourably influenced by alacepril therapy, with significant decreases in plasma aldosterone, ANP and BNP levels[1]. |
| Synonyms | DU-1219, Cetapril |
| Molecular Weight | 406.5 |
| Formula | C20H26N2O5S |
| Cas No. | 74258-86-9 |
| Smiles | C([C@@H](CSC(C)=O)C)(=O)N1[C@H](C(N[C@@H](CC2=CC=CC=C2)C(O)=O)=O)CCC1 |
| Relative Density. | 1.281g/cm3 |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (67.65 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.92 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.